Journal
NANOSCALE
Volume 9, Issue 33, Pages 12096-12109Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7nr02558k
Keywords
-
Categories
Funding
- Prostate Cancer Canada Grant [2011-742]
- Ontario Institute for Cancer Research (OICR)
- London Regional Cancer Program
- National Science Foundation [CMMI NM 333651]
- NIH [R21-EB020946]
- CIHR [1122374]
- Alberta Cancer Foundation
Ask authors/readers for more resources
Angiogenesis is a dynamic process fundamental to the development of solid tumors. Epidermal growth factor-like domain 7 (EGFL7) is a protein whose expression is restricted to endothelial cells undergoing active remodeling that has emerged as a key mediator of this process. EGFL7 expression is associated with poor outcome in several cancers, making it a promising target for imaging or therapeutic strategies. Here, EGFL7 is explored as a molecular target for active neovascularization. Using a combinatorial peptide screening approach, we describe the discovery and characterization of a novel high affinity EGFL7-binding peptide, E7p72, that specifically targets human endothelial cells. Viral nanoparticles decorated with E7p72 peptides specifically target tumor-associated neovasculature with high specificity as assessed by intravital imaging. This work highlights the value of EGFL7 as a target for angiogenic vessels and opens the door for novel targeted therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available